Fred Alger Management LLC Has $163,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Fred Alger Management LLC reduced its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 82.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,317 shares of the company's stock after selling 30,050 shares during the quarter. Fred Alger Management LLC's holdings in Dianthus Therapeutics were worth $163,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DNTH. SG Americas Securities LLC bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $112,000. WINTON GROUP Ltd bought a new position in Dianthus Therapeutics in the second quarter valued at $265,000. Point72 DIFC Ltd acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at $334,000. Virtu Financial LLC bought a new stake in Dianthus Therapeutics during the 1st quarter worth about $390,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth about $630,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Up 0.8 %

Shares of Dianthus Therapeutics stock traded up $0.22 on Friday, hitting $27.24. The stock had a trading volume of 101,970 shares, compared to its average volume of 190,728. The stock has a market cap of $799.47 million, a price-to-earnings ratio of -4.67 and a beta of 1.85. Dianthus Therapeutics, Inc. has a twelve month low of $6.58 and a twelve month high of $33.77. The business's 50 day moving average is $27.91 and its two-hundred day moving average is $26.22.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The firm had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Thursday. Wedbush cut their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, August 9th. Baird R W upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a report on Friday, July 26th. Lifesci Capital upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a research note on Tuesday, June 11th. Finally, Robert W. Baird started coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an "outperform" rating and a $58.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $44.71.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.